The ERF Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the ERF gene in the Raji B lymphocyte cell line. This product serves as a loss-of-function model for dissecting ERF-dependent transcriptional repression and its role in RAS-ERK signaling dynamics.
Raji cells are a well-characterized human B lymphoblastoid line established from a Burkitt??s lymphoma. They exhibit B-cell functions including humoral immunity, antigen presentation, and cytokine production. This cellular background is particularly relevant for investigating oncogenic signaling in B-cell malignancies, where the RAS-ERK pathway is frequently activated.
ERF functions as a transcriptional repressor that accumulates in the nucleus under low ERK activity, binding ETS motifs to suppress target genes such as CCND1, MYC, and FOS. Upon activation of upstream receptors (e.g., EGF, FGF), the RAS-ERK cascade??involving GRB2, SOS1, HRAS, RAF1, MEK1/2, and ERK1/2??phosphorylates ERF. This phosphorylation promotes interaction with XPO1, leading to nuclear export and degradation, thereby relieving repression and allowing cell cycle progression. Disruption of ERF removes this critical feedback checkpoint, resulting in constitutive derepression of proliferative targets.
In the Raji lymphoma background, ERF knockout provides a model to study tumor-suppressive mechanisms that are often subverted by aberrant RAS-ERK activity. ERF normally restrains G1/S transition by repressing CCND1; loss of ERF may therefore mimic oncogenic phenotypes observed in aggressive B-cell lymphomas. This polyclonal knockout population enables the examination of how ERF deficiency impacts drug sensitivity, clonal dynamics, and overall malignant behavior in a relevant cellular context.
Typical applications include investigating ERF-mediated tumor suppression, studying feedback regulation of ERK activity, and evaluating drug responses in lymphoid cancers. Compatible assays include Western blotting for ERF and phospho-ERK, RT-qPCR for CCND1 and MYC, cell proliferation assays, flow cytometry for cell cycle analysis, and drug sensitivity screening. For additional technical details, please contact Ascent Research.
